ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0268

Impact of Flares on Healthcare Resource Usage and PROs in Systemic Lupus Erythematosus Patients
Abstract Number: 0885

Impact of HLA-B27 Status on Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Secukinumab
Abstract Number: 0847

Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity
Abstract Number: 1367

Impact of Ixekizumab on Work Productivity in Non-Radiographic Axial Spondyloarthritis Patients: Results from the COAST-X Trial at 52 Weeks
Abstract Number: 0868

Impact of Proteinuria on the Clearance of Monoclonal Antibodies: Potential Clinical Implications
Abstract Number: 1272

Impact of Remission and Low Disease Activity Status on Hospitalizations Among SLE Patients from the GLADEL Latin American Cohort
Abstract Number: 0992

Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment
Abstract Number: 0873

Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 0480

Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort
Abstract Number: 1583

Impact of Telehealth Implementation on Practice Patterns and Electronic Health Record Utilization During COVID19
Abstract Number: 1685

Impact of the COVID-19 Pandemic Among Children with Rheumatic Diseases from Around the Globe
Abstract Number: 0443

Impact of the COVID-19 Pandemic on Racial and Ethnic Minority Groups Diagnosed with Rheumatic Diseases
Abstract Number: 1804

Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus
Abstract Number: 1568

Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study
Abstract Number: 1717

Impact of Treatments on Favorable Outcome over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from a WCE Model in the ESPOIR Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].